At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Multicenter, Randomized, Double-Blind, 12-Week Treatment, 3-Arm, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
In Brief
A Phase 2 clinical trial evaluating Placebo and RO7017773 for Autism Spectrum Disorder (ASD). Completed, enrolled 104 participants across 21 sites in 4 countries.
Detailed Summary
This study will investigate the efficacy, safety, tolerability, and pharmacokinetics of RO7017773 in participants aged 15-45 years who have been diagnosed with ASD with a score of \>/=50 on the Wechsler Abreviated Scale of Intelligence (WASI-II).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorder (ASD)
CountriesCanada, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartMar 2021
Primary CompletionMay 2024
TodayJul 2026
First PostedMar 6, 2020
Enrollment StartMar 31, 2021
Primary CompletionMay 15, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.3 years ago
Interventions
Placebodrug
Participants will receive oral placebo for approximately 12 weeks.
RO7017773drug
Participants will receive oral RO7017773 for approximately 12 weeks.